AstraZeneca and Sanofi drug Beyfortus is now FDA approved for preventing respiratory problems from RSV infection in infants and toddlers. Antibody engineering enables the drug to last longer in the body, providing protective effects for potentially the entire RSV season.
A panel of experts to the Food and Drug Administration has recommended the agency approve a long-acting antibody drug that can protect infants from the seasonal virus, RSV.
A panel of experts to the Food and Drug Administration has recommended the agency approve a long-acting antibody drug that can protect infants from the seasonal virus, RSV.
A panel of experts to the Food and Drug Administration has recommended the agency approve a long-acting antibody drug that can protect infants from the seasonal virus, RSV.
A panel of experts to the Food and Drug Administration has recommended the agency approve a long-acting antibody drug that can protect infants from the seasonal virus, RSV.